Bayer to divest interventional device business to Boston Scientific
The sale will include the AngioJet (thrombectomy) and Jetstream (atherectomy) systems, and the Fetch2 Aspiration Catheter used in cardiology, radiology and peripheral vascular procedures. Closing is expected in the second half of 2014.
“With this sale, our medical care division can concentrate on innovation and growth in radiology and diabetes care, where we already have a strong presence,” said Dr. Olivier Brandicourt, CEO of Bayer HealthCare.
“The addition of Bayer Interventional will expand our commercial footprint and enhance our ability to provide physicians and healthcare systems with a complete portfolio of solutions to treat challenging vascular conditions,” said Jeff Mirviss, president, Peripheral Interventions, Boston Scientific.
Bayer’s Interventional business accounted for approximately $120 million in sales in 2013.